SCHEMBL4286287

SCHEMBL4286287

COC(=O)c1c[c]ccc1OC(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.42
LMNA P02545 2/20 0.39
ALDH1A1 P00352 3/20 0.37
ACHE P22303 1/20 0.37
ULK1 O75385 1/20 0.37
TSHR P16473 2/20 0.36
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
CFTR P13569 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KDM4E B2RXH2 3/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34
POLB P06746 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319075 0.83 ALDH1A1 (0.46) IRAK4LMNAALDH1A1ACHEIDO1
SCHEMBL2443988 0.83 GAA (0.45) LMNAALDH1A1TSHRCFTRHSD17B10
SCHEMBL4294652 0.79 KDM4E (0.43) LMNAALDH1A1TSHRCFTRHSD17B10
SCHEMBL4284044 0.77 KMT2A (0.50) LMNAALDH1A1TSHRHSD17B10TDP1
SCHEMBL130031 0.77 TSHR (0.44) LMNAALDH1A1TSHRCFTRHSD17B10
SCHEMBL6195395 0.76 SLC6A3 (0.40) LMNAALDH1A1TSHRCFTRHSD17B10
SCHEMBL6200854 0.76 CHEK1 (0.41) LMNAALDH1A1TSHRCFTRHSD17B10
SCHEMBL4036585 0.76 IRAK4 (0.66) IRAK4LMNAALDH1A1ACHETSHR
SCHEMBL2551744 0.75 TSHR (0.42) LMNAALDH1A1TSHRCFTRHSD17B10
SCHEMBL6199939 0.75 KMT2A (0.52) LMNAALDH1A1TSHRHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202880-B2 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors NYCOMED GMBH (DE) 2012-06-19 US disclosed
US-7632844-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2009-12-15 US disclosed
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors NYCOMED GMBH (DE) 2009-07-02 US disclosed
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH 2008-12-25 US disclosed
US-7423046-B2 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors NYCOMED GMBH (DE) 2008-09-09 US disclosed
US-7329676-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2008-02-12 US disclosed
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors ALTANA PHARMA AG (DE) 2007-11-08 US disclosed
CN-1926112-A Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN disclosed
EP-1536798-B1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1539164-B1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2006-12-20 EP disclosed
EP-1725532-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALANA PHARMA AG (DE) 2005-10-27 US disclosed
US-20050239817-A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALTANA PHARMA AG (DE) 2005-10-27 US disclosed
WO-2005085203-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed
EP-1539164-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-15 EP disclosed
EP-1536798-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
WO-2004019944-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2004019945-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239817-A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A IRAK4 472/4885LMNA 4288/4885ALDH1A1 322/4885
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors PDE4A, PDE4B, PDE4D IRAK4 811/4885LMNA 4530/4885ALDH1A1 173/4885
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors PDE4A, PDE4B, PDE3A IRAK4 472/4885LMNA 4288/4885ALDH1A1 322/4885
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A IRAK4 437/4885LMNA 4287/4885ALDH1A1 316/4885
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors PDE4A, PDE4B, PDE3A IRAK4 437/4885LMNA 4335/4885ALDH1A1 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.